Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

Heinz Wiendl, Ralf Gold, Thomas Berger, Tobias Derfuss, Ralf Linker, Mathias Mäurer, Orhan Aktas, Karl Baum, Martin Berghoff, Stefan Bittner, Andrew Chan, Adam Czaplinski, Florian Deisenhammer, Franziska Di Pauli, Renaud Du Pasquier, Christian Enzinger, Elisabeth Fertl, Achim Gass, Klaus Gehring, Claudio Gobbi, Norbert Goebels, Michael Guger, Aiden Haghikia, Hans-Peter Hartung, Fedor Heidenreich, Olaf Hoffmann, Boris Kallmann, Christoph Kleinschnitz, Luisa Klotz, Verena I. Leussink, Fritz Leutmezer, Volker Limmroth, Jan D. Lünemann, Andreas Lutterotti, Sven G. Meuth, Uta Meyding-Lamadé, Michael Platten, Peter Rieckmann, Stephan Schmidt, Hayrettin Tumani, Frank Weber, Martin S. Weber, Uwe K. Zettl, Tjalf Ziemssen, Frauke Zipp, Unknown

Open source

DOI: 10.1177/17562864211039648
Published: 2021-01
Container: Therapeutic Advances in Neurological Disorders
Publisher: SAGE Publications
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1177/17562864211039648,
  title = {Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)},
  author = {Heinz Wiendl and Ralf Gold and Thomas Berger and Tobias Derfuss and Ralf Linker and Mathias Mäurer and Orhan Aktas and Karl Baum and Martin Berghoff and Stefan Bittner and Andrew Chan and Adam Czaplinski and Florian Deisenhammer and Franziska Di Pauli and Renaud Du Pasquier and Christian Enzinger and Elisabeth Fertl and Achim Gass and Klaus Gehring and Claudio Gobbi and Norbert Goebels and Michael Guger and Aiden Haghikia and Hans-Peter Hartung and Fedor Heidenreich and Olaf Hoffmann and Boris Kallmann and Christoph Kleinschnitz and Luisa Klotz and Verena I. Leussink and Fritz Leutmezer and Volker Limmroth and Jan D. Lünemann and Andreas Lutterotti and Sven G. Meuth and Uta Meyding-Lamadé and Michael Platten and Peter Rieckmann and Stephan Schmidt and Hayrettin Tumani and Frank Weber and Martin S. Weber and Uwe K. Zettl and Tjalf Ziemssen and Frauke Zipp and Unknown},
  year = {2021},
  journal = {Therapeutic Advances in Neurological Disorders},
  doi = {10.1177/17562864211039648},
  url = {https://doi.org/10.1177/17562864211039648}
}

RIS

TY  - JOUR
TI  - Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
AU  - Heinz Wiendl
AU  - Ralf Gold
AU  - Thomas Berger
AU  - Tobias Derfuss
AU  - Ralf Linker
AU  - Mathias Mäurer
AU  - Orhan Aktas
AU  - Karl Baum
AU  - Martin Berghoff
AU  - Stefan Bittner
AU  - Andrew Chan
AU  - Adam Czaplinski
AU  - Florian Deisenhammer
AU  - Franziska Di Pauli
AU  - Renaud Du Pasquier
AU  - Christian Enzinger
AU  - Elisabeth Fertl
AU  - Achim Gass
AU  - Klaus Gehring
AU  - Claudio Gobbi
AU  - Norbert Goebels
AU  - Michael Guger
AU  - Aiden Haghikia
AU  - Hans-Peter Hartung
AU  - Fedor Heidenreich
AU  - Olaf Hoffmann
AU  - Boris Kallmann
AU  - Christoph Kleinschnitz
AU  - Luisa Klotz
AU  - Verena I. Leussink
AU  - Fritz Leutmezer
AU  - Volker Limmroth
AU  - Jan D. Lünemann
AU  - Andreas Lutterotti
AU  - Sven G. Meuth
AU  - Uta Meyding-Lamadé
AU  - Michael Platten
AU  - Peter Rieckmann
AU  - Stephan Schmidt
AU  - Hayrettin Tumani
AU  - Frank Weber
AU  - Martin S. Weber
AU  - Uwe K. Zettl
AU  - Tjalf Ziemssen
AU  - Frauke Zipp
AU  - Unknown
PY  - 2021
JO  - Therapeutic Advances in Neurological Disorders
DO  - 10.1177/17562864211039648
UR  - https://doi.org/10.1177/17562864211039648
ER  -

APA

Wiendl, H., Gold, R., Berger, T., Derfuss, T., Linker, R., Mäurer, M., Aktas, O., Baum, K., Berghoff, M., Bittner, S., Chan, A., Czaplinski, A., Deisenhammer, F., Pauli, F. D., Pasquier, R. D., Enzinger, C., Fertl, E., Gass, A., Gehring, K., Gobbi, C., Goebels, N., Guger, M., Haghikia, A., Hartung, H., Heidenreich, F., Hoffmann, O., Kallmann, B., Kleinschnitz, C., Klotz, L., Leussink, V. I., Leutmezer, F., Limmroth, V., Lünemann, J. D., Lutterotti, A., Meuth, S. G., Meyding-Lamadé, U., Platten, M., Rieckmann, P., Schmidt, S., Tumani, H., Weber, F., Weber, M. S., Zettl, U. K., Ziemssen, T., Zipp, F., & Unknown (2021). Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Therapeutic Advances in Neurological Disorders. https://doi.org/10.1177/17562864211039648

Source records

crossref · retrieved 2026-09-26T14:14:22.797Z